Piper Sandler Maintains Neutral on Quest Diagnostics, Lowers Price Target to $130
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Westenberg has maintained a Neutral rating on Quest Diagnostics (NYSE:DGX) and lowered the price target from $145 to $130.
October 16, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler has maintained a Neutral rating on Quest Diagnostics and lowered the price target from $145 to $130.
The lowering of the price target by Piper Sandler could potentially lead to a decrease in the stock price of Quest Diagnostics in the short term as it indicates a lower valuation of the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100